Human USP19/ZMYND9 ORF/cDNA clone-Lentivirus plasmid (NM_006677)
Cat. No.: pGMLP003356
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human USP19/ZMYND9 Lentiviral expression plasmid for USP19 lentivirus packaging, USP19 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.
Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.
Go to
USP19/ZMYND9 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
Catalog ID | pGMLP003356 |
Gene Name | USP19 |
Accession Number | NM_006677 |
Gene ID | 10869 |
Species | Human |
Product Type | Lentivirus plasmid (overexpression) |
Insert Length | 3957 bp |
Gene Alias | ZMYND9 |
Fluorescent Reporter | ZsGreen |
Mammalian Cell Selection | Puromyocin |
Fusion Tag | 3xflag (C-Terminal) |
Promoter | CMV |
Resistance | Amplicin |
ORF Nucleotide Sequence | ATGTCTGGCGGGGCCAGTGCCACAGGCCCAAGGAGAGGGCCCCCAGGACTGGAGGACACCACTAGTAAGAAGAAGCAGAAGGATCGAGCAAACCAGGAGAGCAAGGATGGAGATCCTAGGAAAGAGACAGGGTCTCGATATGTTGCCCAGGCTGGTCTTGAACCTCTGGCCTCAGGTGATCCTTCTGCCTCAGCCTCCCATGCAGCTGGGATCACAGGCTCACGCCACCGTACCCGGCTGTTCTTTCCTTCATCGTCAGGGTCAGCATCCACTCCTCAAGAGGAGCAGACCAAAGAGGGAGCTTGTGAAGACCCTCATGATCTCTTGGCTACTCCCACTCCAGAGTTGTTGCTCGATTGGAGGCAGAGTGCAGAAGAGGTGATTGTCAAGCTTCGTGTGGGAGTAGGTCCCCTGCAGCTGGAGGATGTAGATGCTGCTTTCACAGATACAGACTGTGTGGTGCGGTTTGCAGGTGGTCAGCAGTGGGGTGGTGTCTTCTATGCTGAGATAAAAAGCTCTTGTGCTAAAGTGCAAACCCGCAAGGGCAGTCTCCTGCACCTGACACTGCCCAAAAAGGTGCCTATGCTCACGTGGCCCTCCCTCCTGGTTGAGGCTGATGAACAGCTTTGCATACCACCGCTGAACTCCCAAACCTGCCTCCTGGGCTCAGAGGAGAATTTAGCCCCTTTGGCAGGAGAGAAAGCAGTGCCTCCCGGGAATGACCCAGTCTCTCCAGCCATGGTCCGGAGCAGAAACCCTGGGAAAGATGACTGTGCCAAGGAGGAGATGGCAGTGGCAGCAGATGCTGCAACCTTGGTGGATGAGCCCGAGTCGATGGTGAACCTGGCGTTTGTCAAGAATGACTCGTATGAGAAGGGCCCGGATTCAGTGGTGGTGCACGTGTACGTGAAGGAGATCTGCAGGGACACCTCAAGAGTACTTTTCCGTGAGCAGGACTTCACGCTCATCTTCCAGACCAGGGATGGAAACTTCCTGAGGCTGCACCCGGGCTGTGGGCCCCACACCACCTTCCGTTGGCAGGTGAAGCTCAGGAATCTGATTGAGCCAGAGCAGTGCACCTTCTGTTTCACGGCTTCTCGCATCGACATCTGCCTTCGTAAGAGGCAGAGTCAGCGCTGGGGGGGCCTGGAGGCCCCGGCTGCACGAGTGGGTGGTGCAAAGGTTGCCGTGCCGACAGGTCCAACCCCTCTGGATTCAACCCCACCAGGAGGTGCTCCCCACCCCCTGACAGGCCAGGAGGAGGCCCGGGCTGTGGAGAAGGATAAATCCAAGGCACGATCTGAGGACACAGGGCTAGACAGTGTGGCAACCCGCACACCCATGGAGCATGTAACCCCAAAGCCAGAGACACACCTGGCCTCGCCCAAGCCTACATGCATGGTGCCTCCCATGCCCCACAGCCCAGTTAGTGGAGACAGCGTGGAGGAGGAGGAAGAGGAAGAGAAGAAGGTGTGTCTGCCAGGCTTCACTGGCCTTGTCAATTTAGGCAACACCTGCTTCATGAACAGCGTCATTCAGTCTCTGTCCAACACTCGGGAACTCCGGGACTTCTTCCATGACCGCTCCTTTGAGGCTGAGATCAACTACAACAACCCACTAGGGACTGGTGGGCGTCTGGCCATTGGCTTTGCCGTGCTGCTTCGGGCGCTGTGGAAGGGCACCCACCATGCCTTCCAGCCTTCCAAGTTGAAGGCCATTGTGGCGAGTAAGGCCAGCCAGTTCACAGGCTATGCACAGCATGATGCCCAGGAGTTCATGGCTTTCCTGCTGGATGGGCTGCACGAGGACCTGAATCGCATTCAGAACAAGCCCTACACAGAGACCGTGGATTCAGATGGGCGGCCCGATGAGGTGGTAGCTGAGGAAGCATGGCAGCGGCACAAGATGAGGAATGACTCTTTCATCGTGGACCTATTTCAGGGGCAGTACAAGTCGAAGCTGGTGTGCCCTGTGTGTGCCAAGGTCTCCATCACTTTTGACCCGTTTCTTTATCTGCCGGTGCCCTTGCCACAAAAGCAAAAGGTTCTCCCTGTCTTTTATTTTGCCCGAGAGCCCCACAGCAAGCCCATCAAGTTCCTGGTGAGCGTCAGCAAGGAGAACTCCACTGCGAGCGAAGTATTGGACTCCCTCTCTCAGAGTGTTCATGTGAAGCCTGAGAACCTGCGTTTGGCGGAGGTAATTAAGAATCGTTTTCATCGTGTGTTCCTACCCTCCCACTCACTGGACACTGTGTCCCCATCTGATACGCTCCTCTGCTTTGAGCTGCTATCCTCAGAGTTGGCTAAGGAGCGGGTAGTGGTGCTAGAGGTGCAACAGCGCCCCCAGGTGCCCAGCGTCCCCATCTCCAAGTGTGCAGCCTGCCAGCGGAAGCAACAGTCGGAGGATGAAAAGCTGAAGCGCTGTACCCGGTGCTACCGTGTGGGCTACTGCAACCAGCTCTGCCAGAAAACCCACTGGCCTGACCACAAGGGCCTCTGCCGACCTGAGAACATTGGCTACCCCTTCCTGGTCAGTGTACCTGCCTCACGCCTCACTTATGCCCGCCTCGCTCAGTTGCTAGAGGGCTATGCCCGGTACTCTGTGAGTGTATTCCAGCCACCCTTTCAGCCAGGCCGCATGGCCTTGGAGTCTCAGAGCCCTGGCTGCACCACACTGCTCTCCACAGGTTCCCTGGAGGCTGGGGACAGCGAGAGAGACCCCATTCAGCCACCTGAGCTCCAGCTGGTGACCCCTATGGCTGAGGGGGACACAGGGCTTCCCCGGGTGTGGGCAGCCCCTGACCGGGGTCCTGTGCCCAGCACCAGTGGAATTTCTTCTGAGATGCTGGCCAGTGGGCCCATTGAGGTTGGCTCCTTGCCAGCTGGCGAGAGGGTGTCCCGACCCGAAGCTGCTGTGCCTGGGTACCAGCATCCAAGTGAAGCTATGAATGCCCACACACCCCAGTTCTTCATCTATAAAATTGATTCATCCAACCGAGAGCAGCGGCTAGAGGACAAAGGAGACACCCCACTGGAGCTGGGTGACGACTGTAGCCTGGCTCTCGTCTGGCGGAACAATGAGCGCTTGCAGGAGTTTGTGTTGGTAGCCTCCAAGGAGCTGGAATGTGCTGAGGATCCAGGCTCTGCCGGTGAGGCTGCCCGGGCCGGCCACTTCACCCTGGACCAGTGCCTCAACCTCTTCACACGGCCTGAGGTGCTGGCACCCGAGGAGGCCTGGTACTGCCCACAGTGCAAACAGCACCGTGAGGCCTCCAAGCAGCTGTTGCTATGGCGCCTGCCAAATGTTCTCATCGTGCAGCTCAAGCGCTTCTCCTTTCGTAGTTTTATCTGGCGTGACAAGATCAATGACTTGGTGGAGTTCCCTGTTAGGAACCTGGACCTGAGCAAGTTCTGCATTGGTCAGAAAGAGGAGCAGCTGCCCAGCTACGATCTATATGCTGTCATCAACCACTATGGAGGCATGATTGGTGGCCACTACACTGCCTGTGCACGCCTGCCCAATGATCGTAGCAGTCAGCGCAGTGACGTGGGCTGGCGCTTGTTTGATGACAGCACAGTGACAACGGTAGACGAGAGCCAGGTTGTGACGCGTTATGCCTATGTACTCTTCTACCGCCGGCGGAACTCTCCTGTGGAGAGGCCCCCCAGGGCAGGTCACTCTGAGCACCACCCAGACCTAGGCCCTGCAGCTGAGGCTGCTGCCAGCCAGGCTTCCCGGATTTGGCAGGAGCTGGAGGCTGAGGAGGAGCCGGTGCCTGAGGGGTCTGGGCCCCTGGGTCCCTGGGGGCCCCAAGACTGGGTGGGCCCCCTACCACGTGGCCCTACCACACCAGATGAGGGCTGCCTCCGGTACTTTGTCCTGGGCACCGTGGCGGCTTTGGTGGCCCTCGTGCTCAACGTGTTCTATCCTCTGGTATCCCAGAGTCGCTGGAGATGA |
ORF Protein Sequence | MSGGASATGPRRGPPGLEDTTSKKKQKDRANQESKDGDPRKETGSRYVAQAGLEPLASGDPSASASHAAGITGSRHRTRLFFPSSSGSASTPQEEQTKEGACEDPHDLLATPTPELLLDWRQSAEEVIVKLRVGVGPLQLEDVDAAFTDTDCVVRFAGGQQWGGVFYAEIKSSCAKVQTRKGSLLHLTLPKKVPMLTWPSLLVEADEQLCIPPLNSQTCLLGSEENLAPLAGEKAVPPGNDPVSPAMVRSRNPGKDDCAKEEMAVAADAATLVDEPESMVNLAFVKNDSYEKGPDSVVVHVYVKEICRDTSRVLFREQDFTLIFQTRDGNFLRLHPGCGPHTTFRWQVKLRNLIEPEQCTFCFTASRIDICLRKRQSQRWGGLEAPAARVGGAKVAVPTGPTPLDSTPPGGAPHPLTGQEEARAVEKDKSKARSEDTGLDSVATRTPMEHVTPKPETHLASPKPTCMVPPMPHSPVSGDSVEEEEEEEKKVCLPGFTGLVNLGNTCFMNSVIQSLSNTRELRDFFHDRSFEAEINYNNPLGTGGRLAIGFAVLLRALWKGTHHAFQPSKLKAIVASKASQFTGYAQHDAQEFMAFLLDGLHEDLNRIQNKPYTETVDSDGRPDEVVAEEAWQRHKMRNDSFIVDLFQGQYKSKLVCPVCAKVSITFDPFLYLPVPLPQKQKVLPVFYFAREPHSKPIKFLVSVSKENSTASEVLDSLSQSVHVKPENLRLAEVIKNRFHRVFLPSHSLDTVSPSDTLLCFELLSSELAKERVVVLEVQQRPQVPSVPISKCAACQRKQQSEDEKLKRCTRCYRVGYCNQLCQKTHWPDHKGLCRPENIGYPFLVSVPASRLTYARLAQLLEGYARYSVSVFQPPFQPGRMALESQSPGCTTLLSTGSLEAGDSERDPIQPPELQLVTPMAEGDTGLPRVWAAPDRGPVPSTSGISSEMLASGPIEVGSLPAGERVSRPEAAVPGYQHPSEAMNAHTPQFFIYKIDSSNREQRLEDKGDTPLELGDDCSLALVWRNNERLQEFVLVASKELECAEDPGSAGEAARAGHFTLDQCLNLFTRPEVLAPEEAWYCPQCKQHREASKQLLLWRLPNVLIVQLKRFSFRSFIWRDKINDLVEFPVRNLDLSKFCIGQKEEQLPSYDLYAVINHYGGMIGGHYTACARLPNDRSSQRSDVGWRLFDDSTVTTVDESQVVTRYAYVLFYRRRNSPVERPPRAGHSEHHPDLGPAAEAAASQASRIWQELEAEEEPVPEGSGPLGPWGPQDWVGPLPRGPTTPDEGCLRYFVLGTVAALVALVLNVFYPLVSQSRWR |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
---|---|---|
Target Antibody | GM-Tg-g-IP2255-Ab | Anti-USP19 monoclonal antibody |
Target Antigen | GM-Tg-g-IP2255-Ag | USP19 protein |
ORF Viral Vector | pGMLP003356 | Human USP19 Lentivirus plasmid |
ORF Viral Vector | pGMPC001303 | Human USP19 Mammalian (Non-Viral Vector) plasmid |
ORF Viral Vector | vGMLP003356 | Human USP19 Lentivirus particle |
Target information
Target ID | GM-IP2255 |
Target Name | USP19 |
Gene ID | 10869, 71472, 707512, 361190, 101081789, 476627, 514587, 100053587 |
Gene Symbol and Synonyms | 8430421I07Rik,USP19,ZMYND9 |
Uniprot Accession | O94966 |
Uniprot Entry Name | UBP19_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Not Available |
Disease | Not Available |
Gene Ensembl | ENSG00000172046 |
Target Classification | Not Available |
Protein ubiquitination controls many intracellular processes, including cell cycle progression, transcriptional activation, and signal transduction. This dynamic process, involving ubiquitin conjugating enzymes and deubiquitinating enzymes, adds and removes ubiquitin. Deubiquitinating enzymes are cysteine proteases that specifically cleave ubiquitin from ubiquitin-conjugated protein substrates. This protein is a ubiquitin protein ligase and plays a role in muscle wasting. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2017]
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.